2,2,2-Tris(2-fluorophenyl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2,2,2-Tris(2-fluorophenyl)acetamide
• 化学式: C₂₀H₁₄F₃NO
• 分子量: 341.3
• InChiKey: KBNIQGUEGFKMGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2358750A2

  公开（公告）日：2011-08-24
• US9428568B2
  申请人：——

  公开号：US9428568B2

  公开（公告）日：2016-08-30
• [EN] CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION<br/>[FR] DERIVES CARBONYLAMINO PERMETTANT D'OBTENIR UNE IMMUNOREGULATION
  申请人：POSEIDON PHARMACEUTICALS AS

  公开号：WO2003004010A1

  公开（公告）日：2003-01-16

  The present invention relates to the use of a particular group of carbonylamino derivatives for the treatment or alleviation of diseases or conditions relating to immune regulation.
• [EN] COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR MODULER UNE FUSION CELLULE-CELLULE VIA DES CANAUX POTASSIQUES ACTIVÉS PAR LE CALCIUM DE CONDUCTANCE INTERMÉDIAIRE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010053584A2

  公开（公告）日：2010-05-14

  Compositions and methods are provided for modulating cell-cell fusion by using agents that modulate expression, activity, or function of intermediate- conductance calcium-activated potassium (SK4) channel. In some embodiments, the compositions and methods of the invention provide for inhibition of multi-nucleated osteoclastogenesis and cell-cell fusion, especially cell fusion involving macrophages. In such embodiments, the compositions can comprise inhibitory nucleic acids, monoclonal antibodies or small molecule inhibitors of the SK4 channels and find use in preventing and/or treating various diseases or disorders including bone loss, autoimmune and inflammatory diseases or disorders, implant and transplant rejection, and cancer metastasis. In other embodiments, the compositions and methods of the invention provide for activation of cell-cell fusion. Also provided are methods to screen for SK4 channel modulators (inhibitors or activators) that modulate cell-cell fusion, particularly macrophage cell fusion.